{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:31:38Z","timestamp":1762522298772},"reference-count":30,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Based on very high response rates in the relapsed and refractory setting, brentuximab vedotin and the programmed cell death protein 1 (PD-1) inhibitors, nivolumab and pembrolizumab, have quickly been incorporated into clinical trials for first- and second-line therapy of Hodgkin lymphoma. Preliminary data show that brentuximab vedotin alone is not adequate therapy for newly diagnosed Hodgkin lymphoma in older patients, but modestly decreases the risk of relapse when combined with adriamycin, vinblastine, and dacarbazine in patients with previously untreated advanced-stage disease. In second-line therapy, combining brentuximab vedotin with conventional chemotherapy or with PD-1 inhibitors as pretransplant salvage is associated with high overall and complete response rates, although further follow up is needed to assess whether posttransplant outcomes are improved. Although these new drugs are well tolerated when given as single agents, unexpected toxicities have been encountered with combination regimens, specifically severe pulmonary toxicity with the bleomycin and brentuximab vedotin combination and frequent infusion-related reactions. There is concern with the use of PD-1 inhibitors as first-line therapy due to the theoretical potential for more frequent or severe immune-mediated toxicities in patients who have not received prior chemotherapy. Aside from these concerns, these new agents have the potential to improve outcomes for patients even further, bringing us closer to eradicating recurrent Hodgkin lymphoma.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.317","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"317-323","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution"],"prefix":"10.1182","volume":"2017","author":[{"given":"Nancy L.","family":"Bartlett","sequence":"first","affiliation":[{"name":"Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"18","key":"2019111703263238000_B1","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111703263238000_B2","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"2019111703263238000_B3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"9980","key":"2019111703263238000_B4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2019111703263238000_B5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111703263238000_B6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"22","key":"2019111703263238000_B7","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V128.22.1110.1110","article-title":"CheckMate 205 update with minimum 12-month follow up: a phase 2 study of nivolumab in Patients with relapsed\/refractory classical Hodgkin lymphoma","volume":"128","author":"Timmerman","year":"2016","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111703263238000_B8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hon.2437_124","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow-up of the phase 2 CheckMate 205 trial","volume":"35","author":"Fanale","year":"2017","journal-title":"Hematol Oncol"},{"issue":"19","key":"2019111703263238000_B9","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111703263238000_B10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111703263238000_B11","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2019111703263238000_B12","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood.V126.23.3982.3982","article-title":"Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma","volume":"126","author":"LaCasce","year":"2015","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111703263238000_B13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/hon.2440_6","article-title":"Phase I\/II study of brentuximab vedotin in refractory\/relapsed Hodgkin lymphoma patients treated by chemotherapy (ICE) in second line before autologous transplantation","volume":"35","author":"Stamatoullas","year":"2017","journal-title":"Hematol Oncol"},{"issue":"22","key":"2019111703263238000_B14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood.V128.22.1834.1834","article-title":"Safety and activity of brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (Rel\/Ref) classical Hodgkin lymphoma (cHL): initial results of a phase I\/II trial","volume":"128","author":"Cassaday","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111703263238000_B15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood.V126.23.582.582","article-title":"Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)","volume":"126","author":"Garcia-Sanz","year":"2015","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111703263238000_B16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hon.2437_73","article-title":"Interim results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"35","author":"Herrera","year":"2017","journal-title":"Hematol Oncol"},{"issue":"suppl 2","key":"2019111703263238000_B17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hon.2437_72","article-title":"Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed \/ refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412)","volume":"35","author":"Diefenbach","year":"2017","journal-title":"Hematol Oncol"},{"issue":"26","key":"2019111703263238000_B18","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111703263238000_B19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hon.2437_68","article-title":"Results of a phase II study of brentuximab vedotin in the first line treatment of Hodgkin lymphoma patients considered unsuitable for standard chemotherapy (BREVITY)","volume":"35","author":"Gibb","year":"2017","journal-title":"Hematol Oncol"},{"issue":"2 suppl 1","key":"2019111703263238000_B20","first-page":"13","article-title":"Brentuximab vedotin in combination with dacarbazine or bendamustine for frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: interim results of a multi-cohort phase 2 study","volume":"14","author":"Yasenchak","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"issue":"suppl 2","key":"2019111703263238000_B21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/hon.2438_28","article-title":"Brentuximab-vedotin and bendamustine is a feasible and effective drug combination as first-line treatment of Hodgkin lymphoma in the elderly (HALO TRIAL)","volume":"35","author":"Gallamini","year":"2017","journal-title":"Hematol Oncol"},{"issue":"22","key":"2019111703263238000_B22","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1182\/blood.V128.22.4154.4154","article-title":"A PHASE 1\/2 clinical trial of brentuximab-vedotin and bendamustin in elderly patients with previously untreated advanced Hodgkin lymphoma (HALO STUDY. NCT identifier: 02467946): Preliminary report","volume":"128","author":"Gallamini","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2019111703263238000_B23","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111703263238000_B24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood.V124.21.292.292","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed advanced stage Hodgkin lymphoma: long term outcomes","volume":"124","author":"Connors","year":"2014","journal-title":"Blood"},{"key":"2019111703263238000_B25"},{"issue":"16","key":"2019111703263238000_B26","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2019111703263238000_B27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/hon.2437_69","article-title":"Brentuximab vedotin consolidation to reduce radiation use in patients with limited stage non-bulky Hodgkin lymphoma: an update from a phase 2 clinical trial","volume":"35","author":"Park","year":"2017","journal-title":"Hematol Oncol"},{"issue":"15","key":"2019111703263238000_B28","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1200\/jco.2015.33.15_suppl.8505","article-title":"Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: a phase II trial","volume":"33","author":"Abramson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111703263238000_B29","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2019111703263238000_B30","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V124.21.806.806","article-title":"Novel chimeric antigen receptor T cells for the treatment of Hodgkin lymphoma","volume":"124","author":"Ruella","year":"2014","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/317\/1250912\/hem00044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/317\/1250912\/hem00044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T14:48:27Z","timestamp":1574520507000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/317\/21189\/Emerging-role-of-novel-therapies-in-Hodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.317","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}